CervoMed (CRVO)

Executive Summary

CervoMed is a clinical-stage biotechnology company pioneering a novel approach to treating neurodegenerative diseases by targeting reversible synaptic dysfunction with its lead asset, neflamapimod, an oral p38 alpha kinase inhibitor. The company is advancing neflamapimod into Phase 3 for Dementia with Lewy Bodies (DLB), a precision medicine strategy focused on early-stage patients. In addition to DLB, CervoMed is evaluating neflamapimod in multiple Phase 2 trials for indications such as moderate to severe acute ischemic stroke and nonfluent variant primary progressive aphasia (nfvPPA). Recent Phase 2 data in DLB showed positive signals, supporting the progression to pivotal studies. With a low market capitalization (~$35M) and a focused pipeline, CervoMed represents a high-risk, high-reward opportunity in the neurodegenerative space.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 3 trial in Dementia with Lewy Bodies70% success
• Q3 2026Phase 2 topline data for neflamapimod in moderate to severe acute ischemic stroke40% success
• Q4 2026Phase 2 topline data for neflamapimod in nonfluent variant primary progressive aphasia30% success